Cabaletta Bio (NASDAQ:CABA) Shares Up 10.3% – Here’s Why

Cabaletta Bio, Inc. (NASDAQ:CABA) was up 10.3% during trading on Wednesday . The stock traded as high as $3.09 and last traded at $3.21. Approximately 1,342,561 shares changed hands during mid-day trading, a decline of 64% from the average daily volume of 3,731,450 shares. The stock had previously closed at $2.91.

Cabaletta Bio News Summary

Here are the key news stories impacting Cabaletta Bio this week:

• Positive Sentiment: HC Wainwright improved its EPS forecasts for several periods, including Q3 and Q4 2026, Q1–Q4 2027, FY2026 and FY2027. The firm now expects a loss of $1.35 per share in FY2026 versus its prior forecast of $1.51, and a loss of $1.29 in FY2027 versus $1.48 previously. These narrower projected losses suggest better expected operating performance and are likely supporting sentiment toward Cabaletta Bio (CABA). Cabaletta Bio stock information
• Positive Sentiment: The most significant revision was for FY2028, with HC Wainwright moving its estimate to a $0.74-per-share loss from a $1.41 loss. The firm continues to forecast a transition to profitability by FY2030, with expected earnings of $0.89 per share, reinforcing the longer-term potential of Cabaletta Bio’s pipeline.
• Neutral Sentiment: Despite the upgrades, Cabaletta Bio is still expected to report losses in the coming periods, including approximately $0.31 per share in quarterly losses during late 2026 and early 2027. The current-year consensus remains a loss of $1.34 per share, so investors are likely focused on the pace of improvement rather than near-term profits.
• Negative Sentiment: HC Wainwright reduced its FY2029 EPS forecast to a $0.68 loss from a $0.64 loss and cut its FY2030 earnings forecast to $0.89 from $1.11. These downward long-term revisions temper the bullish impact of the nearer-term upgrades and highlight uncertainty around Cabaletta Bio’s path to sustainable profitability.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Jefferies Financial Group reaffirmed a “buy” rating on shares of Cabaletta Bio in a research note on Wednesday, June 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Cabaletta Bio in a research note on Friday, July 17th. Wells Fargo & Company lowered their price objective on shares of Cabaletta Bio from $4.00 to $3.00 and set an “equal weight” rating for the company in a report on Friday, August 14th. Wall Street Zen cut Cabaletta Bio from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $30.00 target price on shares of Cabaletta Bio in a report on Monday, May 4th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.33.

Cabaletta Bio Trading Up 6.7%

The stock’s fifty day moving average price is $2.87 and its 200 day moving average price is $3.06. The stock has a market cap of $526.42 million, a P/E ratio of -1.98 and a beta of 3.30.

Cabaletta Bio (NASDAQ:CABA) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.03. As a group, sell-side analysts forecast that Cabaletta Bio, Inc. will post -1.34 earnings per share for the current year.

Institutional Trading of Cabaletta Bio

A number of hedge funds have recently made changes to their positions in the stock. Jennison Associates LLC raised its position in shares of Cabaletta Bio by 4.8% in the 4th quarter. Jennison Associates LLC now owns 8,905,699 shares of the company’s stock worth $19,503,000 after purchasing an additional 408,162 shares during the last quarter. GSA Capital Partners LLP bought a new stake in Cabaletta Bio during the 2nd quarter valued at about $2,079,000. Renaissance Technologies LLC raised its holdings in Cabaletta Bio by 33.8% in the first quarter. Renaissance Technologies LLC now owns 2,036,663 shares of the company’s stock worth $5,479,000 after buying an additional 514,080 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Cabaletta Bio by 63.8% in the first quarter. Dimensional Fund Advisors LP now owns 740,648 shares of the company’s stock worth $1,990,000 after buying an additional 288,609 shares during the last quarter. Finally, 683 Capital Management LLC bought a new position in shares of Cabaletta Bio in the fourth quarter worth approximately $851,000.

Cabaletta Bio Company Profile

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.